497 related articles for article (PubMed ID: 27031658)
1. Cystic fibrosis: a model system for precision medicine.
Martiniano SL; Sagel SD; Zemanick ET
Curr Opin Pediatr; 2016 Jun; 28(3):312-7. PubMed ID: 27031658
[TBL] [Abstract][Full Text] [Related]
2. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
Burgener EB; Moss RB
Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
[TBL] [Abstract][Full Text] [Related]
3. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
4. Entering the era of highly effective modulator therapies.
Dave K; Dobra R; Scott S; Saunders C; Matthews J; Simmonds NJ; Davies JC
Pediatr Pulmonol; 2021 Feb; 56 Suppl 1():S79-S89. PubMed ID: 33434412
[TBL] [Abstract][Full Text] [Related]
5. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
6. Ion Channel Modulators in Cystic Fibrosis.
Gentzsch M; Mall MA
Chest; 2018 Aug; 154(2):383-393. PubMed ID: 29750923
[TBL] [Abstract][Full Text] [Related]
7. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
[TBL] [Abstract][Full Text] [Related]
8. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Kuk K; Taylor-Cousar JL
Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
[TBL] [Abstract][Full Text] [Related]
9. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Southern KW; Murphy J; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
[TBL] [Abstract][Full Text] [Related]
10. Mutation-specific dual potentiators maximize rescue of CFTR gating mutants.
Veit G; Da Fonte DF; Avramescu RG; Premchandar A; Bagdany M; Xu H; Bensinger D; Stubba D; Schmidt B; Matouk E; Lukacs GL
J Cyst Fibros; 2020 Mar; 19(2):236-244. PubMed ID: 31678009
[TBL] [Abstract][Full Text] [Related]
11. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
Yang H; Ma T
Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
[TBL] [Abstract][Full Text] [Related]
12. In utero and postnatal ivacaftor/lumacaftor therapy rescues multiorgan disease in CFTR-F508del ferrets.
Evans IA; Sun X; Liang B; Vegter AR; Guo L; Lynch TJ; Zhang Y; Zhang Y; Yi Y; Yang Y; Feng Z; Park SY; Shonka A; McCumber H; Qi L; Wu P; Liu G; Lacina A; Wang K; Gibson-Corley KN; Meyerholz DK; Limoli DH; Rosen BH; Yan Z; Bartels DJ; Engelhardt JF
JCI Insight; 2024 Apr; 9(8):. PubMed ID: 38646935
[TBL] [Abstract][Full Text] [Related]
13. Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy.
Connett GJ
Drug Des Devel Ther; 2019; 13():2405-2412. PubMed ID: 31409974
[TBL] [Abstract][Full Text] [Related]
14. Ivacaftor as salvage therapy in a patient with cystic fibrosis genotype F508del/R117H/IVS8-5T.
Carter S; Kelly S; Caples E; Grogan B; Doyle J; Gallagher CG; McKone EF
J Cyst Fibros; 2015 Jul; 14(4):e4-5. PubMed ID: 25698453
[TBL] [Abstract][Full Text] [Related]
15. The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy.
Lommatzsch ST; Taylor-Cousar JL
Ther Adv Respir Dis; 2019; 13():1753466619844424. PubMed ID: 31027466
[TBL] [Abstract][Full Text] [Related]
16. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Heneghan M; Southern KW; Murphy J; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD010966. PubMed ID: 37983082
[TBL] [Abstract][Full Text] [Related]
17. Ivacaftor potentiation of multiple CFTR channels with gating mutations.
Yu H; Burton B; Huang CJ; Worley J; Cao D; Johnson JP; Urrutia A; Joubran J; Seepersaud S; Sussky K; Hoffman BJ; Van Goor F
J Cyst Fibros; 2012 May; 11(3):237-45. PubMed ID: 22293084
[TBL] [Abstract][Full Text] [Related]
18. Patient personalized translational tools in cystic fibrosis to transform data from bench to bed-side and back.
Arora K; Yang F; Brewington J; McPhail G; Cortez AR; Sundaram N; Ramananda Y; Ogden H; Helmrath M; Clancy JP; Naren AP
Am J Physiol Gastrointest Liver Physiol; 2021 Jun; 320(6):G1123-G1130. PubMed ID: 33949881
[TBL] [Abstract][Full Text] [Related]
19. Corrector combination therapies for F508del-CFTR.
Hanrahan JW; Matthes E; Carlile G; Thomas DY
Curr Opin Pharmacol; 2017 Jun; 34():105-111. PubMed ID: 29080476
[TBL] [Abstract][Full Text] [Related]
20. Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.
Bulloch MN; Hanna C; Giovane R
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1055-1072. PubMed ID: 28891346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]